亚洲 · 股市与财经 · Vietnam Investment Review

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

来源：Vietnam Investment Review · 越南 8 小时前

Biopharmaceutical firm CSL paid 355 million US dollars upfront to Alentis to commercialise lixudebart, pledging up to 1.2 billion US dollars in milestone payments for rare disease…

在 Vietnam Investment Review 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (vir.com.vn)

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

推荐阅读

DBS tops trades in smaller board lots on debut of revised SGX framework

Selected 11 stocks see immediate uptake of smaller board lot sizes on SGX

Sensex Today | Stock Market Highlights: Market ends higher for 2nd straight day; Nifty reclaims 22,700

Why Kotak Mahindra Bank shares are outperforming Nifty 50 and Bank Nifty in the last two months? Experts explain

More about the Nobel prize winner in Physics

ยอด FDI เวียดนาม 9 เดือนแรกปี 69 ทะยาน 76.4% ทะลุ 5 หมื่นล้านดอลล์

CSL secures lixudebart licensing deal with Alentis for 355 million dollars

分享

推荐阅读

DBS tops trades in smaller board lots on debut of revised SGX framework

Selected 11 stocks see immediate uptake of smaller board lot sizes on SGX

Sensex Today | Stock Market Highlights: Market ends higher for 2nd straight day; Nifty reclaims 22,700

Why Kotak Mahindra Bank shares are outperforming Nifty 50 and Bank Nifty in the last two months? Experts explain

More about the Nobel prize winner in Physics

ยอด FDI เวียดนาม 9 เดือนแรกปี 69 ทะยาน 76.4% ทะลุ 5 หมื่นล้านดอลล์